Abstract
The novel coronavirus SARS-CoV-2 emerged in 2019 and subsequently spread throughout the world, causing over 529 million cases and 6 million deaths thus far. In this study, we formulate a continuous-time Markov chain model to investigate the influence of superspreading events (SSEs), defined here as public or social events that result in multiple infections over a short time span, on SARS-CoV-2 outbreak dynamics. Using Gillespie’s direct algorithm, we simulate a continuous-time Markov chain model for SARS-CoV-2 spread under multiple scenarios: first, with neither hospitalisation nor quarantine; second, with hospitalisation, quarantine, premature hospital discharge, and quarantine violation; and third, with hospitalisation and quarantine but neither premature hospital discharge nor quarantine violation. We also vary quarantine violation rates. Results indicate that, in most cases, SSE-dominated outbreaks are more variable but less severe than non-SSE-dominated outbreaks, though the most severe SSE-dominated outbreaks are more severe than the most severe non-SSE-dominated outbreaks. SSE-dominated outbreaks are outbreaks with relatively higher SSE rates. In all cases, SSE-dominated outbreaks are more sensitive to control measures, with premature hospital discharge and quarantine violation substantially reducing control measure effectiveness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is supported by National Science Foundation under the grant number DMS 2028297.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used openly available data that were originally used in Agusto et al. "To isolate or not to isolate: The impact of changing behavior on COVID-19 transmission." BMC Public Health 22.1 (2022): 1-20.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
